Mosaic ImmunoEngineering Reports Decreased Net Loss and Financial Challenges in Q3 2025

Mosaic ImmunoEngineering, Inc. reported a net loss of $165,361 for the third quarter of 2025, a decrease from the $186,730 loss recorded in the same period of the previous year. For the nine months ending September 30, 2025, the company’s net loss was $518,709, down from $768,939 in the prior year. The company did not generate any revenue during this period, and its total operating expenses decreased to $144,358 for the third quarter, compared to $186,430 in the same quarter of 2024. The reduction in expenses was primarily attributed to lower research and development costs, which fell to $16,039 from $39,599 year-over-year, reflecting a decrease in payroll and related costs due to reduced employee commitments.

Mosaic's financial position showed a significant decline in cash and cash equivalents, which dropped to $31,761 as of September 30, 2025, from $115,019 at the end of 2024. The company’s total liabilities increased to $7,362,181, up from $6,929,785 at the end of the previous fiscal year. The stockholders’ deficit also widened to $7,306,883 from $6,788,174, primarily due to the accumulated deficit growing to $9,357,029 from $8,838,320. The company continues to face challenges in raising capital, which is critical for its ongoing operations and development efforts.

Strategically, Mosaic ImmunoEngineering is focused on advancing its cancer therapy initiatives. The company entered into a Binding Term Sheet with Oncotelic Therapeutics, Inc. in April 2024, aiming to acquire rights to certain cancer therapies and AI technologies. However, this agreement expired on June 30, 2025, without a definitive agreement being reached. The company has also been involved in advisory services under a Master Services Agreement with Oncotelic, earning $14,000 for such services during the nine months ended September 30, 2025.

Operationally, Mosaic has not reported any significant changes in customer counts or product adoption rates, as it remains in a development stage without generating revenue. The company’s employee headcount has not been disclosed, but it has indicated a need for additional personnel to support its research and development efforts. The company’s ability to continue operations is highly dependent on its capacity to secure additional funding, as it anticipates that its current cash reserves will not meet operational needs for the next twelve months.

Looking ahead, Mosaic ImmunoEngineering acknowledges substantial uncertainty regarding its ability to raise capital, which is essential for its future operations. The company has no current arrangements for additional financing and faces potential challenges due to market conditions and economic factors, including inflation and recession risks. The management has expressed concerns that without sufficient funding, the company may be forced to cease operations altogether, raising significant doubt about its ability to continue as a going concern.